Subcutaneous Extravasation of Sr-89: Usefulness of Bremsstrahlung Imaging in Confirming Sr-89 Extravasation and in the Decision Making for the Choice of Treatment Strategies for Local Radiation Injuries Caused by Sr-89 Extravasation

Document Type : Case report

Authors

1 Department of Nuclear Medicine, Graduate School of Medicine, Osaka City University, Japan

2 Department of Radiological Sciences, Ibaraki Prefectural University of HealthSciences, Japan

3 Department of Radiology, Osaka City University Hospital, Japan

4 Deaprtment of Dermatology, Graduate School of Medicine, Osaka City University, Japan

Abstract

A male patient in his 20s presented at our clinic with pain caused by bone metastases of the primitive neuroectodermal tumor, and Sr-89 was administrated to palliate the pain. After receiving the injection, the patient complained of a slight burning pain at the catheterized area. Slight reddening and small circular swelling (diameter, 0.5 cm) were observed at the catheterized area. Sr-89 extravasation was suspected. To estimate the amount of subcutaneous Sr-89 leakage, bremsstrahlung imaging was immediately performed. We speculated that the skin-absorbed dose from the subcutaneous Sr-89 leakage was 1.78 Gy. The mildest clinical sign of local radiation injury was erythema. The received dose was higher than 3 Gy, and the time of onset was from 2 to 3 weeks. In our patient, local radiation injuries (LRIs) did not occur. Though requiring further verification, subsequent bremsstrahlung imaging and estimation of the skin-absorbed dose from the subcutaneous Sr-89 leakage are useful in confirming Sr-89 extravasation and in the decision making for the choice of treatment strategies for LRIs caused by Sr-89 extravasation.

Keywords

Main Subjects


  1. Williams G, Palmer MR, Parker JA, Joyce R. Extravazation of therapeutic yttrium-90-ibritumomab tiuxetan (zevalin): A case report. Cancer Biother Radiopharm 2006; 1(2): 101-5.
  2. Committee for Radionuclide Therapy of Japan Radioisotope Association. Q2-6 Treatment of the extravasation of Sr-89, Q&A of the part of safety management in Manual of palliative treatment with Sr-89 for painful bone metastases (Ver.4)(JAPANESE). Tokyo: Committee for Radionuclide Therapy of Japan Radioisotope Association, 2009.
  3. Kobayashi M, Asada Y, Suzuki S, Koga S. Estimation of skin absorbed doses due to subcutaneous leakage of radioactive pharmaceuticals. Nihon Hoshasen Anzenkanrigakukaishi 2003; 2(2):82-6.
  4. Uchiyama M, Narita H, Makino M, Sekine H, Mori Y, Fukumitsu N et al. Strontium-89 therapy and imaging with bremsstrahlung in bone metastases. Clin Nucl Med 1997;22(9):605-9.
  5. Narita H, Uchiyama M, Ooshita T, Hirase K, Makino M, Mori Y et al. Imaging of strontium-89 uptake with bremsstrahlung using NaI scintillation camera. KakuIgaku 1996; 33(11):1207-12.
  6. Narita H, Hirase K, Uchiyama M, Fukushi M. New knowledge about the bremsstrahlung image of strontium-89 with the scintillation camera. Ann Nucl Med 2012;26(7):603-7.
  7. Yamaguchi I, Togashi A. Dosimetric Consequences of Interstitial Extravasation Following i.v.Administration of Tl-201.Hokenbutsuri 2002;37(1):50-5.
  8. International Commission on Radiation Units and measurements. Dosimetry of external beta rays for radiation protection (ICRU report 56). Bethesda: ICRU, 1997.
  9. International atomic energy agency. Diagnosis and treatment of radiation injuries. Vienna: IAEA, 1998.
  10. Fukuda Y. [Discussions about radiation injuries]. KakuIgaku 2003;40(2):213-20.
  11. Committee for Radionuclide Therapy of Japan Radioisotope Association. 5-3 Dose and Injection, Clinical use in Manual of palliative treatment with Sr-89 for painful bone metastases (Ver.4)(JAPANESE). Tokyo: Committee for Radionuclide Therapy of Japan Radioisotope Association, 2009.
  12. Minsky BD, Siddon RL, Recht A, Nagel JS. Dosimetry of aqueous 32P after soft-tissue infiltration following attempted intravenous administration. Health Phys 1987;52(1):87-9.
  13. Shapiro B, Pillay M, Cox PH. Dosimetric consequences of interstitial extravasation following i.v.administration of a radiopharmaceutical.Eur J Nucl Med 1987; 12(10):522-3.
  14. Oda H, Hara H, Ueda O, Kawamata H, Sakai H, Katou Y et al. Underlying examination in the imaging of 89Sr bremsstrahlung radiation. Nihon Hoshasen Gijutsu Gakkai Zasshi 2010;66(7):764-73.